This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McVay, C. S.
Right arrow Articles by Rolfe, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McVay, C. S.
Right arrow Articles by Rolfe, R. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2000, p. 2254-2258, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

In Vitro and In Vivo Activities of Nitazoxanide against Clostridium difficile

Catherine S. McVay and Rial D. Rolfe*

Department of Microbiology and Immunology, Texas Tech University Health Sciences Center, Lubbock, Texas 79430

Received 16 December 1999/Returned for modification 31 March 2000/Accepted 26 May 2000

We have used the hamster model of antibiotic-induced Clostridium difficile intestinal disease to evaluate nitazoxanide (NTZ), a nitrothiazole benzamide antimicrobial agent. The following in vitro and in vivo activities of NTZ in the adult hamster were examined and compared to those of metronidazole and vancomycin: (i) MICs and minimum bactericidal concentrations (MBCs) against C. difficile, (ii) toxicity, (iii) ability to prevent C. difficile-associated ileocecitis, and (iv) propensity to induce C. difficile-associated ileocecitis. The MICs and MBCs of NTZ against 15 toxigenic strains of C. difficile were comparable to those of vancomycin or metronidazole. C. difficile-associated ileocecitis was induced with oral clindamycin and toxigenic C. difficile in a group of 60 hamsters. Subgroups of 10 hamsters were given six daily intragastric treatments of NTZ (15, 7.5, and 3.0 mg/100 g of body weight [gbw]), metronidazole (15 mg/100 gbw), vancomycin (5 mg/100 gbw), or saline (1 ml/100 gbw). Animals receiving saline died 3 days post-C. difficile challenge. During the treatment period, NTZ (>= 7.5 mg/100 gbw), like metronidazole and vancomycin, prevented outward manifestations of clindamycin-induced C. difficile intestinal disease. Six of ten hamsters on a scheduled dose of 3.0 mg of NTZ/100 gbw survived for the complete treatment period. Of these surviving animals, all but three died of C. difficile disease by between 3 and 12 days following discontinuation of antibiotic therapy. Another group of hamsters received six similar daily doses of the three antibiotics, followed by an inoculation with toxigenic C. difficile. All of the NTZ-treated animals survived the 15-day postinfection period. Upon necropsy, all hamsters appeared normal: there were no gross signs of toxicity or C. difficile intestinal disease, nor was C. difficile detected in the cultures of the ceca of these animals. By contrast, vancomycin and metronidazole treatment induced fatal C. difficile intestinal disease in 20 and 70% of recipients, respectively.

* Corresponding author. Mailing address: Department of Microbiology and Immunology, Texas Tech University Health Sciences Center, Lubbock, TX 79430. Phone: (806) 743-2548. Fax: (806) 743-2334. E-mail: micrdr{at}ttuhsc.edu.

Antimicrobial Agents and Chemotherapy, September 2000, p. 2254-2258, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Williams, O. M., Spencer, R. C. (2009). The management of Clostridium difficile infection. Br Med Bull 0: ldp021v1-ldp021 [Abstract] [Full Text]  
  • Halsey, J. (2008). Current and future treatment modalities for Clostridium difficile-associated disease. Am J Health Syst Pharm 65: 705-715 [Abstract] [Full Text]  
  • Kokkotou, E., Moss, A. C., Michos, A., Espinoza, D., Cloud, J. W., Mustafa, N., O'Brien, M., Pothoulakis, C., Kelly, C. P. (2008). Comparative Efficacies of Rifaximin and Vancomycin for Treatment of Clostridium difficile-Associated Diarrhea and Prevention of Disease Recurrence in Hamsters. Antimicrob. Agents Chemother. 52: 1121-1126 [Abstract] [Full Text]  
  • Hecht, D. W., Galang, M. A., Sambol, S. P., Osmolski, J. R., Johnson, S., Gerding, D. N. (2007). In Vitro Activities of 15 Antimicrobial Agents against 110 Toxigenic Clostridium difficile Clinical Isolates Collected from 1983 to 2004. Antimicrob. Agents Chemother. 51: 2716-2719 [Abstract] [Full Text]  
  • Jodlowski, T. Z, Oehler, R., Kam, L. W, Melnychuk, I. (2006). Emerging Therapies in the Treatment of Clostridium difficile-Associated Disease. The Annals of Pharmacotherapy 40: 2164-2169 [Abstract] [Full Text]  
  • Surowiec, D., Kuyumjian, A. G, Wynd, M. A, Cicogna, C. E (2006). Past, Present, and Future Therapies for Clostridium difficile-Associated Disease. The Annals of Pharmacotherapy 40: 2155-2163 [Abstract] [Full Text]  
  • Anton, P. M., O'Brien, M., Kokkotou, E., Eisenstein, B., Michaelis, A., Rothstein, D., Paraschos, S., Kelly, C. P., Pothoulakis, C. (2004). Rifalazil Treats and Prevents Relapse of Clostridium difficile-Associated Diarrhea in Hamsters. Antimicrob. Agents Chemother. 48: 3975-3979 [Abstract] [Full Text]  
  • Bailey, J. M, Erramouspe, J. (2004). Nitazoxanide Treatment for Giardiasis and Cryptosporidiosis in Children. The Annals of Pharmacotherapy 38: 634-640 [Abstract] [Full Text]  
  • Guttner, Y., Windsor, H. M., Viiala, C. H., Dusci, L., Marshall, B. J. (2003). Nitazoxanide in Treatment of Helicobacter pylori: a Clinical and In Vitro Study. Antimicrob. Agents Chemother. 47: 3780-3783 [Abstract] [Full Text]  
  • Stettler, M., Fink, R., Walker, M., Gottstein, B., Geary, T. G., Rossignol, J. F., Hemphill, A. (2003). In Vitro Parasiticidal Effect of Nitazoxanide against Echinococcus multilocularis Metacestodes. Antimicrob. Agents Chemother. 47: 467-474 [Abstract] [Full Text]  
  • Sisson, G., Goodwin, A., Raudonikiene, A., Hughes, N. J., Mukhopadhyay, A. K., Berg, D. E., Hoffman, P. S. (2002). Enzymes Associated with Reductive Activation and Action of Nitazoxanide, Nitrofurans, and Metronidazole in Helicobacter pylori. Antimicrob. Agents Chemother. 46: 2116-2123 [Abstract] [Full Text]  
  • Pelaez, T., Alonso, R., Perez, C., Alcala, L., Cuevas, O., Bouza, E. (2002). In Vitro Activity of Linezolid against Clostridium difficile. Antimicrob. Agents Chemother. 46: 1617-1618 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»